1 / 38

Analytical considerations

Analytical considerations. Drs. Jan Welink. Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009. Guidance. FDA Guidance for Industry Bioanalytical method validation, May 2001 ICH Guidance for industry

hisoki
Download Presentation

Analytical considerations

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Analytical considerations Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009

  2. Guidance • FDA Guidance for Industry • Bioanalytical method validation, May 2001 • ICH Guidance for industry • Validation of analytical methods: definitions and terminology, June 1995 • Validation of analytical procedures: methodology, November 1996

  3. GCP/GLP • GCP/GLP compliance • Clinical studies have to be performed under conditions complying with the principles of Good Clinical Practice, and for analytical methods and sample data handling conditions complying with the principles of Good Laboratory Practice are required. • For older studies without statement of compliance with the above mentioned principles, the assessor should rely on the quality of the submitted report.

  4. Choice of method • Method used for the determination of drugs and/or metabolites should be: Sensitive Accurate Discriminative Precise

  5. Sensitivity • Method should be able to quantify the drug in the sampled specimen at least 10 % of the maximum concentration reached after dosing. Limit of Quantification (LOQ): 1/10 Cmax

  6. Discriminative • The method should be able to discriminate between the selected analyte and interfering compounds from the environment or from other compounds administered simultaneously

  7. Accuracy • The method must be accurate enough to measure the true value (concentration) of the analyte in a relative small sample

  8. Precision • The analytical method should be precise enough to reveal identical results when the procedure is applied repeatedly to multiple aliquots of a single homogeneous volume of the biological matrix

  9. Validation To measure is to know!

  10. Validation • Range • Accuracy • Precision • Robustness • Specificity • Detection limit (LOD) • Quantification limit (LOQ) • Linearity

  11. Validation-specificity • Investigation of specificity should be conducted during the validation phase of the assay • The procedures used to demonstrate specificity should be clearly reported • Must be applied with structurally similar materials • Choices base on scientific judgements

  12. Validation-specificity

  13. Validation-LOD • Various methods possible visual evaluation • minimum level at which the analyte can be detected reliably signal-to noise • 3:1 ratio is acceptable standard deviation of the slope and response • LOD = 3.3 σ / S • σ = standard deviation of the response • S = slope of the calibration curve

  14. Validation-LOQ • Based on signal-to noise • Reliable quantification is a 10:1 ratio • Based on SD of the response and the slope • LOQ = 10 σ / S • σ = standard deviation of the response • S = slope of the calibration curve

  15. Validation LOQ, LOD and SNR • Limit of Quantitation • Limit of Detection • Signal to Noise Ratio Peak BLOQ Peak ALOD noise Baseline

  16. Validation-LOD/LOQ Recommended data: • The LOD and LOQ and the method used for the LOQ should be presented • The limits should be validated by the analyses of a suitable number of samples prepared at the LOD and LOQ limits

  17. Validation-linearity • Should be evaluated across the range of concentrations expected during the study • A minimum of five concentrations used in the range is recommended • The correlation coefficient, y-intercept slope of the regression and residual sum of squares should be submitted • Deviations from the regression line should be analysed for evaluating linearity

  18. Validation-linearity

  19. Validation-range • The specified range is derived from linearity studies and should cover the extremes of the concentrations probably reached during the study • The range should be justified in the report based on scientific information

  20. Validation-accuracy • Accuracy should be assessed on samples spiked with known amounts of the analyte • Accuracy should be assessed using determinations over a minimum of 3 concentration levels (low, medium and high) • Accuracy should be reported as percent recovery from the added amount

  21. Validation-accuracy HQC MQC LQC

  22. Validation-precision • Repeatability • concentrations covering the specified range • Intermediate precision • Like days, analysts, equipment • Reproducibility • Determined if analyses take place in separate periods

  23. Validation-accuracy/precision Accuracy/precision:

  24. Validation-accuracy/precision Between-day: Intra-day:

  25. Validation-accuracy/precision: Accuracy/precision calibrators:

  26. Validation-accuracy/precision FDA Accuracy Precision within-run between-run within-run between-run normally: <15% LLOQ: <20% normally: <15% LLOQ: <20%

  27. Validation-robustness • Robustness should be considered during development phase • Shows the reliability of the analytical method with respect to variations in the method parameters • In case variations occur they should be suitably controlled and if present adequately tested and documented

  28. Validation-robustness Typical examples: • Stability of the analytical solutions • Influence of variations of pH of the mobile phase • Influence of variations of mobile phase composition • Influence of temperature and flow rate • Extraction conditions • pH and extraction time

  29. Validation-robustness

  30. Validation-recovery Recovery: • Extraction efficiency analytical method • consistent • precise • reproducible Recovery: 80% 75% 91% 97% 65% 73% Recovery: 15% 16% 13% 15% 16% 14% mean: 81.1% CV: 14.7% mean: 14.8% CV: 7.9%

  31. Validation-stability Stability assessed prior subject sample analysis! • Required data • Freeze and thaw stability • Short term temperature stability • Long term stability • Stock solution stability • Post preparation stability

  32. Analysis clinical samples • The analytical method should be validated before the start of obtaining clinical samples. • Each analytical run should contain sufficient QC samples at the beginning, middle and end at at least 3 levels (LQC, MQC and HQC). QC QC QC QC QC QC

  33. Analysis clinical samples • Acceptation or rejection of a run should be predefined before the actual start of the analysis of the clinical samples. FDA criteria QC QC QC QC QC QC

  34. Analysis clinical samples • All samples of 1 subject in 1 run • Subject sample reanalysis should be predefined before the actual start of the analysis of the clinical samples. Reasons: - improper sample injection - mail function - concentration > HLOQC - unexpected value - PK reason QC QC QC QC QC QC

  35. Analysis clinical samples - unexpected value - PK reason

  36. Report • All methods should be covered by adequate Standard Operating Procedures (SOP’s) for general and analysis specific procedures • Before the start of an analytical procedure an adequate study plan has to be written or be incorporated in the study protocol

  37. Report • A specific detailed description of the bioanalytical method should be written • All experiments used to make claims or draw conclusions should be presented in the report • GLP compliance/inspections/audits

  38. End

More Related